Reassuring Registry Data on Going Into TAVR Sans Symptoms
Transcatheter aortic valve replacement (TAVR) got some preliminary affirmation for asymptomatic or minimally symptomatic severe aortic stenosis in a retrospective registry study. Of participants who got elective TAVR, the one in five who had minimal symptoms before the procedure tended to have good outcomes that compared favorably against the majority of more symptomatic peers: Fewer […]
PPI Still Common With Self-Expanding TAVR
Need for a pacemaker after transfemoral transcatheter aortic valve replacement (TAVR) with a self-expanding device was both common and impactful for mortality, but the risk appeared to be modifiable, international registry data showed. Of patients treated with an Acurate neo/neo2 (approved outside the U.S.) or Evolut PRO/PRO+ valve, 11.3% needed new permanent pacemaker implantation (PPI) […]
Real-World Data Affirms Next-Gen TAVR Device Advantage
PHOENIX — The newer generation Evolut transcatheter aortic valve replacement (TAVR) device improved on procedural and possibly safety characteristics, the TVT registry showed. The Evolut FX device reduced need for device repositioning and cut procedure time, without a change in valve hemodynamics, at 30 days compared with the Evolut Pro+ device, reported Wah Wah Htun, […]
Transapical Transcatheter Mitral Valve Replacement Trial Raises Questions
PHOENIX — Global experience with the novel Intrepid transapical transcatheter mitral valve replacement (TMVR) device through 2 years showed high risks of mortality and complications, raising concerns that might not be alleviated by the planned shift to a transfemoral approach. In the analysis pooling data from a pilot study and the APOLLO trial, the high-risk […]
TEER Improves Quality of Life With Severe Tricuspid Regurgitation
NEW ORLEANS — Transcatheter edge-to-edge repair (TEER) of severely regurgitant tricuspid valves improved outcomes, largely in terms of quality of life, the TRILUMINATE Pivotal trial showed. Compared with medical therapy alone, the percutaneous placement of an investigational TriClip device to hold the leaflets together was favored in a Bayesian analysis with a win ratio of […]
Skipping Antiplatelets Altogether Not Such a Bad Idea for Select TAVR Patients
Following transcatheter aortic valve replacement (TAVR), the optimal antithrombotic regimen for some people may be no antithrombotics at all, according to provocative registry data from Japan. Compared with the single antiplatelet (SAPT) or dual antiplatelet (DAPT) approaches for TAVR patients without any other indications for antiplatelet or anticoagulation therapy, the non-antithrombotic strategy was not associated […]
Is TAVR in Small Aortic Annuli Better With Self-Expanding Valves?
BOSTON — Transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli had better hemodynamic results with a self-expandable than a balloon-expandable valve, with suggestion of better clinical outcomes too, in the France-TAVI registry. Mean gradient was significantly lower with self-expanding Medtronic CoreValve Evolut Pro or R devices at the end of the procedure […]
Fate of Transcatheter Tricuspid Devices: Will it Be Repair or Replacement?
CHICAGO — Discussing their predictions on where transcatheter technologies in the tricuspid space are going, some experts said they favored the odds of replacement over repair when devices are ready to be commercialized. Yet making the case for transcatheter tricuspid valve repair was Paul Sorajja, MD, of Minneapolis Heart Institute at Abbott Northwestern Hospital, who […]
TAVR Chugging Along at 5 Years in SURTAVI Trial
Researchers keeping an eye on the long-term outcomes of people undergoing transcatheter aortic valve replacement (TAVR) reported encouraging results in both clinical and economic terms, according to two reports from the Transcatheter Cardiovascular Therapeutics (TCT) meeting. The 5-year incidence of all-cause mortality or disabling stroke among people in the SURTAVI trial was no different between […]